Key result
Natriuretic peptides are the most thoroughly evaluated biomarkers and show the most promise for the diagnosis or exclusion of acute heart failure, while other biomarkers add prognostic utility.
Why the study?
What is the clinical utility of various biomarkers for the diagnosis and prognostication of acute decompensated heart failure?
What is the clinical utility of various biomarkers for the diagnosis and prognostication of acute decompensated heart failure?
Natriuretic peptides remain the most promising biomarkers for diagnosing acute heart failure, while other biomarkers offer additional prognostic value.
Supports prioritizing natriuretic peptides for acute HF diagnosis; leaves open optimal multimarker integration in practice.
Acute decompensated heart failure (ADHF) is a prominent condition whose frequency is increasing, especially in the context of an aging population. The ability to discern the cause of undifferentiated dyspnea in acute presentations is an increasing struggle. In this review, we seek to explore the various biomarkers that have been studied for the diagnosis of ADHF and their respective clinical utilities as the most recent data would suggest. Natriuretic peptides, galectin-3, soluble ST2, adrenomedullin, cardiac troponin-T, neutrophil gelatinase-associated lipocalin, and copeptin are reviewed. Of these biomarkers, natriuretic peptides are the most thoroughly evaluated and show the most promise for diagnosis or exclusion of acute heart failure, though other biomarkers can add significant utility in the form of prognostication.
No takes yet. Share an insight, caveat, or question.
Rosenbaum et al. (2015) conducted a review in Acute Decompensated Heart Failure (ADHF). Biomarkers (natriuretic peptides, galectin-3, soluble ST2, adrenomedullin, cardiac troponin-T, NGAL, copeptin) was evaluated on Diagnosis or exclusion of acute heart failure and prognostication. Natriuretic peptides are the most thoroughly evaluated biomarkers and show the most promise for the diagnosis or exclusion of acute heart failure, while other biomarkers add prognostic utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: